The failure of several Phase II/III clinical trials in Alzheimer's disease (AD) with drugs targeting β-amyloid accumulation in the brain fuelled an increasing interest in alternative treatments against tau pathology, including approaches targeting tau phosphatases/kinases, active and passive immunization, and anti-tau aggregation. The most advanced tau aggregation inhibitor (TAI) is methylthioninium (MT), a drug existing in equilibrium between a reduced (leuco-methylthioninium) and oxidized form (MT+). MT chloride (methylene blue) was investigated in a 24-week Phase II clinical trial in 321 patients with mild to moderate AD that failed to show significant positive effects in mild AD patients, although long-term observations (50 weeks) and biomarker studies suggested possible benefit. The dose of 138 mg/day showed potential benefits on cognitive performance of moderately affected AD patients and cerebral blood flow in mildly affected patients. Further clinical evidence will come from the large ongoing Phase III trials for the treatment of AD and the behavioral variant of frontotemporal dementia on a new form of this TAI, more bioavailable and less toxic at higher doses, called TRx0237. More recently, inhibitors of tau acetylation are being actively pursued based on impressive results in animal studies obtained by salsalate, a clinically used derivative of salicylic acid.
from #Medicine via ola Kala on Inoreader http://ift.tt/28WhPsJ
via IFTTT
Αρχειοθήκη ιστολογίου
-
►
2023
(138)
- ► Φεβρουαρίου (74)
- ► Ιανουαρίου (64)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
▼
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
-
▼
Ιουνίου
(946)
-
▼
Ιουν 26
(21)
- Sensors, Vol. 16, Pages 969: Sensor Network-Based ...
- Sensors, Vol. 16, Pages 924: Verification of Geome...
- Sensors, Vol. 16, Pages 944: A Tightly-Coupled GPS...
- Endoxifen, a New Treatment Option for Mania: A Dou...
- Studying the Role of Alveolar Macrophages in Breas...
- Circulating MicroRNA Quantification Using DNA-bind...
- Cutaneous Surgical Denervation: A Method for Testi...
- Novel synthetic lethality screening method identif...
- The Effect of Teriparatide on Fracture Healing of ...
- MicroRNA-21 Promotes Proliferation of Fibroblast-L...
- Tau-Centric Targets and Drugs in Clinical Developm...
- Effect of Water-Glass Coating on HA and HA-TCP Sam...
- Phytochemical, Antimicrobial, and Toxicological Ev...
- Synthesis and Potent Antiprotozoal Activity of Mon...
- Complementary Medicine Health Literacy among a Pop...
- Identification of Plants That Inhibit Lipid Drople...
- Paeoniflorin and Albiflorin Attenuate Neuropathic ...
- Expressions of Matrix Metalloproteinases 2, 7, and...
- High Expression of PTGR1 Promotes NSCLC Cell Growt...
- Focal Segmental Glomerulosclerosis: Genetics, Mech...
- Glia-Neuron Interactions in the Retina Can Be Stud...
-
▼
Ιουν 26
(21)
- ► Φεβρουαρίου (793)
Αναζήτηση αυτού του ιστολογίου
Κυριακή 26 Ιουνίου 2016
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Αλέξανδρος Γ. Σφακιανάκης Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,0030693260717...
-
heory of COVID-19 pathogenesis Publication date: November 2020Source: Medical Hypotheses, Volume 144Author(s): Yuichiro J. Suzuki ScienceD...
-
Alimentary Pharmacology &Therapeutics, EarlyView. https://ift.tt/2qECBIJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.